Status:
COMPLETED
EPIPAGE 2 - 10-year Follow-up (RECONAI PROJECT)
Lead Sponsor:
Institut National de la Santé Et de la Recherche Médicale, France
Conditions:
Pre-Term
Development, Child
Eligibility:
All Genders
10-11 years
Brief Summary
Epipage 2 (Epidemiological study on small gestational ages) is a prospective population-based national cohort implemented to better understand the short, mid and long term future of premature children...
Detailed Description
The objectives of this new follow-up phase are to study: * the relationships between prematurity, early growth and cardiometabolic disorders * the relationship between parenting educational skills an...
Eligibility Criteria
Inclusion
- Children initially included in the Epipage 2 study,
- Not lost to follow up (i.e. having participated in at least one of the Epipage 2 surveys since the age of 1 year),
- Neither parent has expressed a definitive refusal to participate in the follow-up study.
Exclusion
- Refusal of the investigation by one of the two parents or holders of parental authority,
- Residence abroad
Key Trial Info
Start Date :
February 17 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 21 2022
Estimated Enrollment :
2383 Patients enrolled
Trial Details
Trial ID
NCT05243901
Start Date
February 17 2022
End Date
December 21 2022
Last Update
May 16 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
INSERM (National Institute of Health and Medical Research) - Université Paris Cité, INRAE, Obstetrical, Perinatal and Pediatric Epidemiology Research Team (EPOPé Team) Center for Epidemiology and Statistics
Paris, France, 74014